TP53 and soft tissue sarcoma: These molecules demonstrate stronger antiproliferative capabilities and broader applicability compared with traditional MDM2 inhibitors by restoring p53 stability and activating its downstream apoptotic pathways, particularly showing potential in p53‐dependent tumors such as malignant melanoma and soft tissue sarcomas.